---
title: "BUZZ-Arcturus falls as cystic fibrosis drug shows no improvement in initial analysis"
description: "Shares of Arcturus Therapeuticsfell 61.8% to $8.84 in premarket trading after an initial analysis of its experimental cystic fibrosis therapy showed no improvement in lung function at day 28. However,"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262236126.md"
published_at: "2025-10-22T11:59:48.000Z"
---

# BUZZ-Arcturus falls as cystic fibrosis drug shows no improvement in initial analysis

> Shares of Arcturus Therapeuticsfell 61.8% to $8.84 in premarket trading after an initial analysis of its experimental cystic fibrosis therapy showed no improvement in lung function at day 28. However, day 42 measurements indicated potential improvements. The company plans to start a 12-week safety and preliminary efficacy study in H1 2026. Prior to this news, the stock had risen 36.5% year-to-date.

Shares of Arcturus Therapeutics (ARCT.O) fall 61.8% to $8.84 premarket

Co says an initial analysis comparing lung function from day 1 and day 28 after treatment with its experimental cystic fibrosis therapy did not show improvement in a mid-stage study

However, measurements at day 42 suggests improvements in lung function

Encouraged by early signals of reduction in mucus plugging - ARCT

Experimental inhaled mRNA therapy ARCT-032 generally safe and well tolerated - co

Intend to initiate a 12-week safety and preliminary efficacy study in up to 20 CF participants in H1 2026

CF is an inherited genetic disorder that causes thick, sticky mucus to build up in the body’s organs, primarily affecting the lungs and pancreas

Up to last close, stock had risen 36.5% YTD

### Related Stocks

- [ARCT.US - Arcturus Therapeutics](https://longbridge.com/en/quote/ARCT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Arcturus Therapeutics Maps Near-Term Milestones for CF mRNA Therapy, ARCT-810 at J.P. Morgan Conference | Arcturus Therapeutics CEO Joe Payne presented the company's focus on mRNA therapeutics at the J.P. Morgan Conference, hi | [Link](https://longbridge.com/en/news/272352451.md) |
| Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit | Arcturus Therapeutics (NASDAQ:ARCT) presented at Guggenheim’s 2026 Emerging Outlook Biotech Summit, highlighting its mRN | [Link](https://longbridge.com/en/news/275642293.md) |
| IDT Australia Reports Operational Improvements with New Leadership Team and Realignment Strategy | IDT Australia reported operational improvements under a new leadership team and realignment strategy, with a 20.3% incre | [Link](https://longbridge.com/en/news/276194130.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/en/news/276017486.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.